Insulet is trading at $140.00, up +4.53%, in pre-market on October 15, 2026, versus the October 14 close, a move that appears consistent with a broader defensive rotation into healthcare amid inflation and rate concerns.
- Healthcare was indicated higher pre-market.
- No clear company-specific event was found that explains the gain.
- Insulet announced the U.S. rollout of its Omnipod Discover platform on October 12, but the release did not connect the announcement to share performance.